-
Accomplished Transactional Practitioner
Weiheng has represented clients in many of the largest and most significant M&A and capital markets deals in a variety of industries, including technology, healthcare, and consumer.
-
Comprehensive Transactions Experience
He has worked on numerous private equity and venture capital investment, going-private, joint venture, and restructuring transactions for well-known private equity and venture capital firms and multinational corporations
-
Capital Markets Veteran
Weiheng has advised on many high-profile securities offerings, including Hong Kong IPOs and HKSE listings, and U.S.-registered offerings and NYSE and NASDAQ listings.
-
Trusted Business Advisor
He has extensive and unique experience advising clients on U.S. regulatory and legislative matters, as well as strategic litigation in connection with the ever-evolving Sino-U.S. relations.
Weiheng Chen is a senior partner at Wilson Sonsini, where he has been the head of the firm's Greater China practice since 2010. He started his legal career in New York and has been primarily based in Asia over the last 20 years. Weiheng is known as an accomplished transaction lawyer and trusted business advisor. He has extensive and unique experience in advising clients on U.S. regulatory and legislative matters, as well as strategic litigation in connection with the ever-evolving Sino-U.S. relations.
Weiheng's practice is focused on cross-border mergers and acquisitions, private equity, and capital markets transactions and board-level strategic advice. He has represented clients in many of the largest and most significant M&A and capital markets deals in a variety of industries, including technology, healthcare, and consumer. Weiheng has worked on numerous private equity and venture capital investment, going-private, joint venture, and restructuring transactions for well-known private equity and venture capital firms and multinational corporations. In addition, he has advised on many high-profile securities offerings, including Hong Kong IPOs and HKSE listings, and U.S.-registered offerings and NYSE and NASDAQ listings.
Weiheng Chen is a senior partner at Wilson Sonsini, where he has been the head of the firm's Greater China practice since 2010. He started his legal career in New York and has been primarily based in Asia over the last 20 years. Weiheng is known as an accomplished transaction lawyer and trusted business advisor. He has extensive and unique experience in advising clients on U.S. regulatory and legislative matters, as well as strategic litigation in connection with the ever-evolving Sino-U.S. relations.
Weiheng's practice is focused on cross-border mergers and acquisitions, private equity, and capital markets transactions and board-level strategic advice. He has represented clients in many of the largest and most significant M&A and capital markets deals in a variety of industries, including technology, healthcare, and consumer. Weiheng has worked on numerous private equity and venture capital investment, going-private, joint venture, and restructuring transactions for well-known private equity and venture capital firms and multinational corporations. In addition, he has advised on many high-profile securities offerings, including Hong Kong IPOs and HKSE listings, and U.S.-registered offerings and NYSE and NASDAQ listings.
- LL.M., Harvard Law School
- Master of Jurisprudence and LL.B., Peking University Law School
- Named “Dealmaker of the Year” finalist for the 2023, 2024, 2025, and 2026 ALB Hong Kong Law Awards
- Named “Managing Partner of the Year” finalist for the 2023 and 2024 ALB Hong Kong Law Awards
- Recognized as a “Dealmaker of the Year - International” finalist for the 2026 ALB China Law Awards
- Designated as one of the "World's Leading Private Equity Lawyers" by IFLR/Euromoney
- Named to the 2023-24 and 2024-25 "A-List: The Visionaries" by China Business Law Journal
- Recognized as a "notable practitioner" by IFLR 1000
- State Bar of New York
- Hong Kong
- LL.M., Harvard Law School
- Master of Jurisprudence and LL.B., Peking University Law School
- Named “Dealmaker of the Year” finalist for the 2023, 2024, 2025, and 2026 ALB Hong Kong Law Awards
- Named “Managing Partner of the Year” finalist for the 2023 and 2024 ALB Hong Kong Law Awards
- Recognized as a “Dealmaker of the Year - International” finalist for the 2026 ALB China Law Awards
- Designated as one of the "World's Leading Private Equity Lawyers" by IFLR/Euromoney
- Named to the 2023-24 and 2024-25 "A-List: The Visionaries" by China Business Law Journal
- Recognized as a "notable practitioner" by IFLR 1000
- State Bar of New York
- Hong Kong
Select Representations
- Represented Boyu Capital, CDH Investments, Centurium Capital, Sequoia Capital, Silver Lake, 6 Dimensions, Warburg Pincus, and other private equity and growth capital funds in connection with various investment and M&A transactions
- Represented technology and healthcare companies such as Tencent, DJI International, and WuXi AppTec in their various investment, M&A, and financing matters
- Advised on the Hong Kong IPOs and HKSE listings of WuXi XDC, LEPU ScienTech Medical Technology, Angel Align Technology, Ascentage Pharma, WuXi AppTec, Wanka Online, WuXi Biologics, Rici Healthcare, Universal Medical, PW MedTech, Dongpeng Holdings, Alibaba.com, Bank of China, and China Shenhua Energy
- Advised on the U.S. public offerings and/or listings of Agora, Ebang International, Tencent Music Entertainment, X Financial, Opera Limited, Puxin Education, Bright Scholar, China Biologic Products, Autohome, China Nepstar Chain Drugstore, and Mindray Medical
- Provided underwriter-side representation to investment banks, including Goldman Sachs, Deutsche Bank, Morgan Stanley, CICC, Citi, JP Morgan, Credit Suisse, Bank of America, and UBS
-
Represented WuXi AppTec in its sale of the Advanced Therapies Unit and U.S. Medical Device Testing Operations
-
Represented Lumentum in the $750 million acquisition of Cloud Light Technology Group
- Represented Boyu Capital in the acquisition of Quasar Medical
- Represented PW Medtech and the acquisition consortium in the $4.6 billion going-private transaction of China Biologic Products, Inc.
-
Represented Warburg Pincus and the acquisition consortium in the $9.7 billion going-private transaction of 58.com
-
Represented SilverLake-led investors in the $2.3 billion PIPE investments in TAL Education
-
Represented the acquisition consortium led by Yunfeng Capital and Alibaba and Boyu Capital in the $1.5 billion going-private transaction of iKang Healthcare
-
Represented the acquisition consortium in the HK$5.6 billion going-private transaction of Dongpeng Holdings
-
Represented the management shareholders and the acquisition consortium in the $3.3 billion going-private transaction of WuXi PharmaTech
-
Represented OmniVision Technologies in its $1.9 billion acquisition by a Chinese consortium of investors
-
Represented Integrated Silicon Solution Inc. in its $640 million sale to a Chinese consortium of investors
-
Represented the acquisition consortium in the $1.9 billion going-private transaction of Shanda Games
-
Represented the founder and the acquisition consortium in the $3 billion going-private transaction of Giant Interactive
-
Represent RDA Microelectronics in its $900 million merger with Tsinghua Unigroup
-
Represented TJOY Holdings in the $400 million sale of its China skincare business to Coty, Inc.
-
Represented State Grid International Development in its $1.72 billion acquisition of power transmission assets in Brazil
-
Represented Waste Management Inc. in its waste-to-energy joint venture with Shanghai Chentou Holdings in China
-
Represented China Huaneng Group in its $3 billion acquisition of Tuas Power in Singapore
-
Represented C-BONS International in the €270 million sale of its China haircare business to Beiersdorf AG
-
Represented CVC Partners in its sale of Adisseo France SAs to ChemChina
-
Represented Bank of China in connection with its strategic sales to Royal Bank of Scotland, UBS, Temasek, and Asian Development Bank
-
Represented Thomson in the combination of its global television business with TCL
Select Representations
- Represented Boyu Capital, CDH Investments, Centurium Capital, Sequoia Capital, Silver Lake, 6 Dimensions, Warburg Pincus, and other private equity and growth capital funds in connection with various investment and M&A transactions
- Represented technology and healthcare companies such as Tencent, DJI International, and WuXi AppTec in their various investment, M&A, and financing matters
- Advised on the Hong Kong IPOs and HKSE listings of WuXi XDC, LEPU ScienTech Medical Technology, Angel Align Technology, Ascentage Pharma, WuXi AppTec, Wanka Online, WuXi Biologics, Rici Healthcare, Universal Medical, PW MedTech, Dongpeng Holdings, Alibaba.com, Bank of China, and China Shenhua Energy
- Advised on the U.S. public offerings and/or listings of Agora, Ebang International, Tencent Music Entertainment, X Financial, Opera Limited, Puxin Education, Bright Scholar, China Biologic Products, Autohome, China Nepstar Chain Drugstore, and Mindray Medical
- Provided underwriter-side representation to investment banks, including Goldman Sachs, Deutsche Bank, Morgan Stanley, CICC, Citi, JP Morgan, Credit Suisse, Bank of America, and UBS
-
Represented WuXi AppTec in its sale of the Advanced Therapies Unit and U.S. Medical Device Testing Operations
-
Represented Lumentum in the $750 million acquisition of Cloud Light Technology Group
- Represented Boyu Capital in the acquisition of Quasar Medical
- Represented PW Medtech and the acquisition consortium in the $4.6 billion going-private transaction of China Biologic Products, Inc.
-
Represented Warburg Pincus and the acquisition consortium in the $9.7 billion going-private transaction of 58.com
-
Represented SilverLake-led investors in the $2.3 billion PIPE investments in TAL Education
-
Represented the acquisition consortium led by Yunfeng Capital and Alibaba and Boyu Capital in the $1.5 billion going-private transaction of iKang Healthcare
-
Represented the acquisition consortium in the HK$5.6 billion going-private transaction of Dongpeng Holdings
-
Represented the management shareholders and the acquisition consortium in the $3.3 billion going-private transaction of WuXi PharmaTech
-
Represented OmniVision Technologies in its $1.9 billion acquisition by a Chinese consortium of investors
-
Represented Integrated Silicon Solution Inc. in its $640 million sale to a Chinese consortium of investors
-
Represented the acquisition consortium in the $1.9 billion going-private transaction of Shanda Games
-
Represented the founder and the acquisition consortium in the $3 billion going-private transaction of Giant Interactive
-
Represent RDA Microelectronics in its $900 million merger with Tsinghua Unigroup
-
Represented TJOY Holdings in the $400 million sale of its China skincare business to Coty, Inc.
-
Represented State Grid International Development in its $1.72 billion acquisition of power transmission assets in Brazil
-
Represented Waste Management Inc. in its waste-to-energy joint venture with Shanghai Chentou Holdings in China
-
Represented China Huaneng Group in its $3 billion acquisition of Tuas Power in Singapore
-
Represented C-BONS International in the €270 million sale of its China haircare business to Beiersdorf AG
-
Represented CVC Partners in its sale of Adisseo France SAs to ChemChina
-
Represented Bank of China in connection with its strategic sales to Royal Bank of Scotland, UBS, Temasek, and Asian Development Bank
-
Represented Thomson in the combination of its global television business with TCL
- Privacy Policy
- Terms of Use
- Accessibility